Drug
Paclitaxel clinical trials
Also written Taxol, BMS-181339, Onxal and Onxol.
Includes 674 studies of Albumin-Bound Paclitaxel and 18 studies of Paclitaxel Liposome.
- studies test it
- 2,132
- open now
- 342
- in phase 3
- 264
- first study started
- 1991
Keep track of what changes. Save the Paclitaxel studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Paclitaxel
- 1,147
- Anzatax
- 165
- Asotax
- 153
- Praxel
- 101
- Bristaxol
- 100
Development codes
Other names
Combined with it in one product
Studies by the year they started
2,121 studies that test it; most in 2015 (98); 4 more planned to start later
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1994 | 10 |
| 1995 | 6 |
| 1996 | 20 |
| 1997 | 38 |
| 1998 | 42 |
| 1999 | 58 |
| 2000 | 59 |
| 2001 | 51 |
| 2002 | 35 |
| 2003 | 42 |
| 2004 | 43 |
| 2005 | 61 |
| 2006 | 73 |
| 2007 | 75 |
| 2008 | 76 |
| 2009 | 73 |
| 2010 | 73 |
| 2011 | 72 |
| 2012 | 74 |
| 2013 | 72 |
| 2014 | 96 |
| 2015 | 98 |
| 2016 | 76 |
| 2017 | 81 |
| 2018 | 73 |
| 2019 | 94 |
| 2020 | 96 |
| 2021 | 85 |
| 2022 | 78 |
| 2023 | 74 |
| 2024 | 77 |
| 2025 | 75 |
| 2026 | 64 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 16
- Phase 1
- 670
- Phase 2
- 1,389
- Phase 3
- 264
- Phase 4
- 26
- No phase
- 53
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 463 · Other 1,669
National Cancer Institute (NCI) (98) · M.D. Anderson Cancer Center (67) · Fudan University (45) · Memorial Sloan Kettering Cancer Center (41) · Gynecologic Oncology Group (34) · Alliance for Clinical Trials in Oncology (27) · Hoffmann-La Roche (26) · Sun Yat-sen University (26)
Often tested with
Tested in the same studies.
Carboplatin (642) · Gemcitabine (292) · Cisplatin (269) · Bevacizumab (154) · Cyclophosphamide (110) · Fluorouracil (99) · Trastuzumab (93) · Doxorubicin (93)
Studies
Open first, then newest update. How each study uses Paclitaxel is read from its arms, and is right about nine times in ten.
Testing it · 2,132
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingPhase 2SWOG Cancer Research NetworkNCT04205968Written as Paclitaxel
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06601309Written as Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06058377Written as Paclitaxel
- Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialRecruitingPhase 3National Cancer Institute (NCI)NCT06096844Written as Nab-paclitaxel
- A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic CancerRecruitingPhase 1/2Theriva Biologics SLNCT07701486Written as Nab-paclitaxel + Gemcitabine
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as Nab-paclitaxel
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06843447Written as Paclitaxel
- Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaNot yet recruitingPhase 1Northwestern UniversityNCT07594548Written as Paclitaxel
- Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial CancerNot yet recruitingPhase 3GlaxoSmithKlineNCT07860450Written as Carboplatin and paclitaxel
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as nab-Paclitaxel (100 mg/m² )
- Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and PaclitaxelRecruitingPhase 2National Cancer Institute (NCI)NCT04449549Written as Nilotinib and Paclitaxel
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingPhase 3Revolution Medicines, Inc.NCT07805954Written as nab-paclitaxel
- Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)RecruitingPhase 2/3BioNTech SENCT06712316Written as Paclitaxel
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Paclitaxel
- A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingPhase 2Medical University of South CarolinaNCT07743190Written as Paclitaxcel
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Xijing HospitalNCT07876154Written as nab-paclitaxel
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck CancerRecruitingPhase 2National Cancer Institute (NCI)NCT07195734Written as Paclitaxel
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingPhase 1Washington University School of MedicineNCT06795009Written as Paclitaxel
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT03424005Written as Nab-Paclitaxel
- US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and ChemotherapyNot yet recruitingPhase 2Emory UniversityNCT07862751Written as Paclitaxel
See all 2,132 studies that test Paclitaxel →
Given in every arm · 1,205 — Paclitaxel is usual care beside what is tested
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Paclitaxel
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE TrialRecruitingPhase 2/3National Cancer Institute (NCI)NCT06203600Written as Paclitaxel
- A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsRecruitingPhase 1/2Verastem, Inc.NCT07020221Written as Gemcitabine + Nab-paclitaxel
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Paclitaxel
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Written as Paclitaxel
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07198074Written as Paclitaxel
- Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung CancerNot yet recruitingPhase 2Canadian Cancer Trials GroupNCT07890493Written as Paclitaxel
- Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT06860529Written as Albumin Paclitaxel
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07061977Written as Paclitaxel
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ TrialRecruitingPhase 2National Cancer Institute (NCI)NCT03907475Written as Nab-paclitaxel
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as Paclitaxel + Carboplatin
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Paclitaxel
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Nab-paclitaxel/Paclitaxel
- A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsRecruitingPhase 3AbbVieNCT07756645Written as Paclitaxel
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsRecruitingPhase 1NiKang Therapeutics, Inc.NCT06586957Written as Paclitaxel
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Paclitaxel
- Window of Opportunity in Preserving Laryngeal Function TrialRecruitingPhase 2Matthew SpectorNCT07423078Written as Paclitaxel
- Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal CancerNot yet recruitingPhase 1Rebecca ArendNCT07772882Written as Paclitaxel
- Repurposing Mefloquine for Pancreatic Cancer TreatmentNot yet recruitingPhase 1University of FloridaNCT07875907Written as gemcitabine and nab paclitaxel
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]RecruitingPhase 3Merck Sharp & Dohme LLCNCT06422143Written as Paclitaxel
Showing 20 of 1,205.
As the comparator · 265 — what is tested is compared with Paclitaxel
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Toripalimab and Nab-Paclitaxel
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingPhase 3Immuneering CorporationNCT07562152Written as GnP
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07060807Written as Paclitaxel
- Propranolol With Chemotherapy or Chemoradiation for Esophageal AdenocarcinomaRecruitingPhase 2Roswell Park Cancer InstituteNCT04682158Written as Paclitaxel
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07419295Written as Paclitaxel
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine CancerRecruitingPhase 3BioNTech SENCT06340568Written as Paclitaxel
- A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06731907Written as Paclitaxel
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07743164Written as Paclitaxel
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Paclitaxel
- A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)RecruitingPhase 3GlaxoSmithKlineNCT07286266Written as Paclitaxel
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312176Written as Paclitaxel
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06841354Written as Paclitaxel
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingPhase 3AstraZenecaNCT06989112Written as Paclitaxel
- A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary CancersRecruitingPhase 2AbbVieNCT07769502Written as Nab-Paclitaxel
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingPhase 3Eli Lilly and CompanyNCT07213804Written as Paclitaxel
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian CancerRecruitingPhase 3Verastem, Inc.NCT06072781Written as Paclitaxel
- Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian CancerRecruitingPhase 3GenmabNCT07564141Written as Paclitaxel
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingPhase 3GenmabNCT07604766Written as Paclitaxel
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Paclitaxel
- A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)RecruitingPhase 3GlaxoSmithKlineNCT07286331Written as Paclitaxel
Showing 20 of 265.
Codes
What other systems call Paclitaxel · ClinicalTrials.gg INT008560
- MeSH (NLM) D017239PaclitaxelConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) P88XT4IS4DPACLITAXELConfirmed FDA, NLM, Wikidata
- RxNorm 56946Confirmed FDA, Wikidata
- Wikidata Q423762paclitaxelConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1411PaclitaxelOne source FDA
- DrugBank DB01229One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D017239 | Paclitaxel | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | P88XT4IS4D | PACLITAXEL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 56946 | — | Confirmed FDA, Wikidata |
| Wikidata | Q423762 | paclitaxel | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1411 | Paclitaxel | One source FDA |
| DrugBank | DB01229 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.